Cytokinetics(NASDAQ) CYTK

Market Cap$9.55B

Since IPO (2004)-21%

5 Year+141%

1 Year+118%

1 Month-10%

$76.90

-5.50%

-4.48Today

After hours$76.72-$0.18 (-0.23%)

Cytokinetics last closing stock price
Metric	Price	Date
Last close	USD 76.76	2026-08-07

Cytokinetics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.48%	USD 77.13	2026-07-31
1 month	-9.57%	USD 84.88	2026-07-08
3 month	-0.2%	USD 76.91	2026-05-08
Year to date	+20.81%	USD 63.54	2025-12-31
1 year	+117.76%	USD 35.25	2025-08-07
3 year	+140.25%	USD 31.95	2023-08-08
5 year	+141.23%	USD 31.82	2021-08-06
Since inception	-20.54%	USD 96.60	2004-04-29

Cytokinetics Financials at a Glance

Market Cap

$9.55B

Revenue (TTM)

$70.96M

Net Income (TTM)

-$894.00M

EPS (TTM)

-$7.22

P/E Ratio

-10.63

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$76.90

Volume

3,604,464.404

Open

$81.23

Price

$76.90

Volume

3,604,464.404

Open

$81.23

Previous Close

$76.76

Daily Range

$75.87 - $81.50

52-Week Range

$32.89 - $88.31

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$76.90

Volume

3,604,464.404

Open

$81.23

Previous Close

$76.76

Daily Range

$75.87 - $81.50

52-Week Range

$32.89 - $88.31

Estimated Earnings Date

Aug 6, 2026

CYTK News

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Jonathan PoncianoJul 14, 2026

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

Sara AppinoMar 9, 2026

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

Sarah SidlowDec 19, 2025

Page 1

CYTK: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cytokinetics

Cytokinetics makes medicines that help heart and skeletal muscles work better. These treatments help people whose muscles are weak or have trouble pumping blood. The company focuses on fixing the tiny biological engines that power every movement in the body.

Muscle Biology in Action

MYQORZO: A medicine used to treat obstructive hypertrophic cardiomyopathy, a condition where thickened heart muscle blocks blood flow; approved by the FDA in December 2025.
Aficamten: The clinical version of MYQORZO currently being tested for additional heart conditions like non-obstructive hypertrophic cardiomyopathy.
Omecamtiv Mecarbil: An investigational drug designed to help the heart pump more blood in patients with severe heart failure.
Neuromuscular Pipeline: Early-stage treatments like CK-089 that aim to improve muscle strength for people with wasting diseases or muscular dystrophy.

Recent Strategic Moves

Partnered with Bayer in late 2024 to bring heart treatments to patients in Japan.
Signed a deal with Sanofi in late 2024 to develop and sell aficamten in China and Taiwan.
Launched a new Phase 3 trial called COMET-HF in late 2024 to confirm how well its heart failure drug works.
Secured funding from Royalty Pharma in 2024 to support the development of new heart medicines.

What Makes the Company Stand Out

Cytokinetics is a leader in muscle biology, focusing on the cytoskeleton, which is the internal structure that helps cells maintain their shape and move. By targeting the specific proteins that control muscle contraction, the company creates highly specialized treatments that differ from traditional heart medications.

Tracking the Progress

Revenue reached $17.8 million in Q4 2025, up 4.9% from $16.9 million in Q4 2024.
Net loss for Q4 2025 was $183 million, compared to a loss of $150 million in Q4 2024.
Operating income was -$178.4 million in Q4 2025, down 28.3% from the previous year.
Market capitalization grew to $8.1 billion by early 2026, up nearly 40% year-over-year.

Evolution to Commercial Scale

Cytokinetics has transitioned from a research-focused firm into a commercial business following the 2025 approval of its first heart medicine. The company continues to build its specialty cardiology franchise by moving several new drug candidates through global clinical trials.

AI Generated • Apr 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

673

CEO

Robert I. Blum, MBA

Website

www.cytokinetics.com

Headquarters

South San Francisco, CA 94080, US

CYTK Financials

Key Financial Metrics (TTM)

Gross Margin

84.97%

Operating Margin

-992.98%

Net Income Margin

-1259.87%

Return on Equity

163.98%

Return on Capital

-98.02%

Return on Assets

-46.45%

Earnings Yield

-9.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.55B

Shares Outstanding

124.43M

Volume

3.60M

Avg. Volume

2.21M

Financials (TTM)

Gross Profit

$60.30M

Operating Income

-$704.62M

EBITDA

-$818.60M

Operating Cash Flow

-$700.91M

Capital Expenditure

-$31.19M

Free Cash Flow

-$732.10M

Cash & ST Invst.

$1.17B

Total Debt

$1.27B

Cytokinetics Performance Analysis

Cytokinetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 94,588,000	34.3%
2023	2023-12-31	USD 7,530,000	-92.0%
2024	2024-12-31	USD 18,474,000	145.3%
2025	2025-12-31	USD 88,039,000	376.6%

Cytokinetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-97.1%
Q4	2025-12-31	817.1%
Q1	2026-03-31	9.0%
Q2	2026-06-30	64.9%

Cytokinetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -4.33	54.6%
2023	2023-12-31	USD -5.45	25.9%
2024	2024-12-31	USD -5.26	-3.4%
2025	2025-12-31	USD -6.54	24.1%

Cytokinetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-127.7%
Q4	2025-12-31	41.2%
Q1	2026-03-31	-11.3%
Q2	2026-06-30	10.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$31.91M

-52.2%

Gross Profit

$29.18M

-54.7%

Gross Margin

91.44%

N/A

Market Cap

$9.55B

N/A

Market Cap/Employee

$14.19M

N/A

Employees

673

N/A

Net Income

-$198.76M

-47.9%

EBITDA

-$191.75M

-77.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$1.17B

+35.8%

Total Debt

$1.27B

+48.1%

Accounts Receivable

$24.43M

+190.5%

Inventory

$380.00K

N/A

Long Term Debt

$1.22B

+48.3%

Short Term Debt

$48.40M

+42.4%

Return on Assets

-46.45%

N/A

Return on Invested Capital

-40.42%

N/A

Free Cash Flow

-$315.56M

-138.4%

Operating Cash Flow

-$305.30M

-138.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ABVXAbivax S.A.

ABVXAbivax S.A.$130.93+0.72%

NUVLNuvalent, Inc.

NUVLNuvalent, Inc.$123.96+0.00%

AXSMAxsome Therapeutics, Inc.

AXSMAxsome Therapeutics, Inc.$212.74+1.24%

RYTMRhythm Pharmaceuticals, Inc.

RYTMRhythm Pharmaceuticals, Inc.$115.63+3.15%

MTSRMetsera, Inc.

MTSRMetsera, Inc.$70.50-0.35%

CORTCorcept Therapeutics Incorporated

CORTCorcept Therapeutics Incorporated$110.77+2.61%

HALOHalozyme Therapeutics, Inc.

HALOHalozyme Therapeutics, Inc.$103.12+20.24%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$133.11+0.16%

TTDThe Trade Desk

TTDThe Trade Desk$13.80-0.22%

NVDANvidia

NVDANvidia$223.96+0.02%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.76+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.11+0.06%

PLTRPalantir Technologies

PLTRPalantir Technologies$172.01+0.10%

INTCIntel

INTCIntel$101.65+0.02%

Questions About CYTK

What is the current price of Cytokinetics?

Cytokinetics is trading at $76.76 per share.

What is the 52-week range for Cytokinetics?

Over the past 52 weeks, Cytokinetics has traded between $32.89 and $88.31.

How much debt does Cytokinetics have?

As of the most recent reporting period, Cytokinetics reported total debt of $1.27B.

How much cash does Cytokinetics have on hand?

Cytokinetics reported $258.38M in cash and cash equivalents in its most recent financial results.

What is Cytokinetics’s dividend yield?

Cytokinetics does not currently have a dividend yield.

Cytokinetics(NASDAQ) CYTK

Cytokinetics Financials at a Glance

CYTK News

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

CYTK Earnings Jump 3,065%

Why Cytokinetics Stock Was a Nearly 5% Winner Today

2 Incredible Growth Stocks to Buy Right Now

Here's Why Cytokinetics Is Rocketing Higher Today

CYTK: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cytokinetics

Muscle Biology in Action

Recent Strategic Moves

What Makes the Company Stand Out

Tracking the Progress

Evolution to Commercial Scale

CYTK Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cytokinetics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CYTK

What is the current price of Cytokinetics?

What is the 52-week range for Cytokinetics?

How much debt does Cytokinetics have?

How much cash does Cytokinetics have on hand?

What is Cytokinetics’s dividend yield?

Premium Investing Services